Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Platinum-resistant Ovarian Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 143pembrolizumab 121Carboplatin 109Bevacizumab 93Cisplatin 69Specimen Handling 62olaparib 51Magnetic Resonance Spectroscopy 51Gemcitabine 41Nivolumab 36Biopsy 36liposomal doxorubicin 34Taxes 33Cyclophosphamide 31Blood Specimen Collection 31niraparib 28lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 23Brachytherapy 22fludarabine 21atezolizumab 21Radiotherapy 21Disulfides 21durvalumab 20dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
afuresertib × Gynecologic × 1 year × Clear all
NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡